Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 6/20 | 0.49 |
| ▸ | MMP3 | P08254 | 5/20 | 0.49 |
| ▸ | MMP1 | P03956 | 3/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481493 | 1.00 | GPR84 (0.55) | GPR84CPB2MMP2MMP3MMP1 | |
| SCHEMBL27622663 | 1.00 | GPR84 (0.55) | GPR84CPB2MMP2MMP3MMP1 | |
| SCHEMBL29014239 | 0.98 | GPR84 (0.52) | GPR84CPB2MMP2MMP3MMP1 | |
| SCHEMBL5180252 | 0.88 | GPR84 (0.53) | GPR84MMP2MMP3MMP1MMP7 | |
| SCHEMBL11655019 | 0.88 | GPR84 (0.53) | GPR84MMP2MMP3MMP1MMP7 | |
| SCHEMBL14672526 | 0.88 | GPR84 (0.53) | GPR84MMP2MMP3MMP1MMP7 | |
| SCHEMBL6560418 | 0.88 | GPR84 (0.53) | GPR84MMP2MMP3MMP1MMP7 | |
| SCHEMBL14672449 | 0.88 | GPR84 (0.53) | GPR84MMP2MMP3MMP1MMP7 | |
| SCHEMBL8749767 | 0.88 | GPR84 (0.53) | GPR84MMP2MMP3MMP1MMP7 | |
| Hexane SCHEMBL11311103 | 0.88 | GPR84 (0.44) | GPR84CPB2MMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3130583-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-0065638-B1 | SUBSTITUTED 7-(4-SUBSTITUTED-CYCLOPENT-2-EN-1-ON-2-YL)-HEPT-2-TRANSENOATES | AMERICAN CYANAMID COMPANY (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4644079-A | Precursors and synthesis of d1-(methyl)-16,16-(dimethyl)-11-alpha, 15-alpha, beta-dihydroxy-9-oxo-2,13,-trans, trans-prostadienoates | AMERICAN CYANAMID COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| US-4549030-A | PROSTAGLANDIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| US-4535173-A | Intermediates for the production of prostaglandins from D-glucose | THE UPJOHN COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
| US-4474979-A | Synthesis of d1-(methyl)-16,16-(dimethyl-11-alpha, 15-alpha, beta-dihydroxy-9-oxo-2,13,-trans,trans-prostadienoates | AMERICAN CYANAMID COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0113561-A2 | Prostaglandin intermediates, their synthesis and their conversion to prostaglandins | THE UPJOHN COMPANY (US) | 1984-07-18 | — | — | EP | disclosed |
| EP-0065638-A1 | Substituted 7-(4-substituted-cyclopent-2-en-1-on-2-yl)-hept-2-transenoates | AMERICAN CYANAMID COMPANY (US) | 1982-12-01 | — | — | EP | disclosed |
| US-4360688-A | Precursors and synthesis of d1-(methyl)-16,16-(dimethyl)-11-alpha, 15-alpha, beta-dihydroxy-9-oxo-2,13,-trans, trans-prostadienoates | AMERICAN CYANAMID COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
| US-4254036-A | 1-Hydroxymethyl-1-oxo-prostane-derivatives of the E, A and F-series | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| EP-0015056-A1 | 1-Hydroxymethyl-1-oxo-prostane derivatives of the E, A and F series | AMERICAN CYANAMID COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | GPR84 20/4885CPB2 4526/4885MMP2 3638/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GPR84 20/4885CPB2 4526/4885MMP2 3638/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GPR84 20/4885CPB2 4526/4885MMP2 3638/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | GPR84 21/4885CPB2 4836/4885MMP2 3575/4885 |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | GPR84 21/4885CPB2 4836/4885MMP2 3575/4885 |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | GPR84 20/4885CPB2 4526/4885MMP2 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.